Kestra Medical Technologies (NASDAQ:KMTS) Director Sells $98,481.60 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Mary Ladone sold 3,908 shares of Kestra Medical Technologies stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $25.20, for a total transaction of $98,481.60. Following the completion of the sale, the director directly owned 37,507 shares of the company’s stock, valued at approximately $945,176.40. The trade was a 9.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Trading Down 3.1%

Kestra Medical Technologies stock opened at $22.85 on Friday. Kestra Medical Technologies, Ltd. has a one year low of $17.34 and a one year high of $30.00. The company’s fifty day moving average price is $25.34 and its two-hundred day moving average price is $22.71. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -9.44 and a beta of 0.62.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The company had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. On average, analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kestra Medical Technologies

Large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. lifted its position in shares of Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after buying an additional 474 shares during the period. Daiwa Securities Group Inc. acquired a new position in Kestra Medical Technologies during the fourth quarter worth $72,000. BNP Paribas Financial Markets lifted its holdings in shares of Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after acquiring an additional 1,638 shares during the period. Brown Brothers Harriman & Co. lifted its holdings in shares of Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey boosted its stake in shares of Kestra Medical Technologies by 34.6% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock valued at $144,000 after purchasing an additional 1,392 shares in the last quarter.

Key Stories Impacting Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra appointed Daniel Finney as Vice President of Research & Development and added him to its executive leadership team. Finney has more than 20 years of Class III medical-device experience and previously led Kestra’s new product development. He will oversee innovation for the Cardiac Recovery System, including strategic partnerships and artificial-intelligence initiatives, providing leadership continuity after the retirement of Phillip Foshee. Kestra Names Daniel Finney Vice President of Research & Development
• Neutral Sentiment: Reported short interest was zero shares as of September 10, unchanged from the prior reporting period. This suggests limited measurable short-selling pressure, but also provides little new information for investors.
• Neutral Sentiment: Analyst expectations remain mixed. BTIG maintains a $32 price target and JPMorgan has a $30 target, while other analysts are more cautious; the reported median target from recent forecasts is $24.50. The upcoming earnings release could prompt additional estimate changes. Kestra earnings preview
• Negative Sentiment: Four directors sold a combined 16,424 shares worth approximately $414,000. The transactions reduced their individual holdings by about 9% to 48%. Because the sales were made to cover tax withholding on vested equity awards, they are less concerning than discretionary selling, though the cluster may weigh on sentiment. SEC insider transaction filings
• Negative Sentiment: Kestra is expected to report a first-quarter loss, adding to concerns about profitability. Its latest reported quarter showed a $0.67 per-share loss, worse than the $0.59 consensus estimate, despite revenue of $28.64 million. Analysts currently forecast a full-year loss of approximately $2.29 per share.

Wall Street Analyst Weigh In

KMTS has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. began coverage on Kestra Medical Technologies in a report on Monday, August 10th. They set an “overweight” rating and a $30.00 price target on the stock. Weiss Ratings cut shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 31st. BTIG Research reiterated a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a report on Wednesday, September 2nd. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Finally, Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $28.14.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient’s heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.

The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.